Skip to main content
Premium Trial:

Request an Annual Quote

Minerva Biolabs Licenses DxS Genotyping System for SARS Diagnostic Development

NEW YORK, June 17 - DxS of Manchester, UK, said today that it has signed a license agreement for its Scorpions PCR-based genotyping technology with Minerva Biolabs of Berlin.

 

Minerva will use the fluorescence-based nucleic acid detection system in its development of a real-time PCR diagnostic test for the SARS virus. The molecular diagnostics firm has already developed Scorpions-based diagnostics for Legionella and Mycoplasma.

 

Steve Little, DxS CEO, said the company is "currently in discussion with a number of other international diagnostics companies with regards to technology licenses in addition to continuing to build our genotyping services business."

 

DxS said that Scorpions is also non-exclusively licensed to Ortho-Clinical Diagnostics in the field of oncology and to a number of oligonucleotide manufacturers.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.